Massey physician-researcher helps develop and lead national breast cancer studies
VCU Massey Cancer Center physician-researcher Charles Geyer, M.D., co-developed and co-led two important national breast cancer clinical trials that were recently presented at the American Society of Clinical Oncology’s annual meeting in Chicago. One study was presented in the “Best of ASCO” Program, which presents the scientific and educational highlights of the meeting.
Novel combination therapy developed at Massey shows strong response in patients with advanced solid tumors
A phase 1 clinical trial testing a novel combination therapy developed by scientists at VCU Massey Cancer Center slowed the growth of cancer in the majority of trial participants, which were patients with advanced solid tumors. Approximately 61 percent of these patients experienced some degree of tumor growth delay, with multiple partial responses and one complete response. A phase 2 study testing the same combination of the drugs sorafenib and pemetrexed in patients with recurrent or metastatic triple negative breast cancer is now open at Massey.
Massey Physicians named Richmond Magazine’s Top Docs 2016
VCU Massey Cancer Center physicians again were recognized in Richmond Magazine’s annual list of “Top Docs.” Featured in the magazine’s April 2016 issue, the list includes 31 doctors from varied specialties who provide oncology-related care to Massey’s patients, including 10 who care for pediatric patients at the Children’s Hospital of Richmond at VCU. The selections were the result of a survey that asked Richmond-area physicians who they would recommend in a range of specialties.
Massey opens clinical trial testing a combination of Viagra and chemo to treat advanced solid tumors
VCU Massey Cancer Center has developed and opened a Phase 1 clinical trial to study the effects of Viagra in combination with chemotherapy to treat patients with progressive, advanced solid tumors. The trial is a result of previous research conducted at Massey by a group of researchers including physician-scientist Andrew Poklepovic, M.D., who is the leading the trial as its principal investigator. Their research demonstrated that regorafenib (trade name Stivarga), a type of chemotherapy, interacts with Viagra (generic name sildenafil), a medication originally developed for erectile dysfunction, to kill tumor cells significantly better than regorafenib alone.
Massey researchers identify patients at risk for stem cell transplant complications
Researchers at VCU Massey Cancer Center’s Bone Marrow Transplant Program have recently published findings from a phase 2 clinical trial that demonstrate lymphocyte recovery in related and unrelated stem cell transplant recipients generally falls into three patterns that are significantly associated with survival. This first-of-its-kind research continues the efforts of principal investigator Amir Toor, M.D., to understand the immune system as a dynamical system that can be modeled to improve stem cell transplantation.